Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Gastrointestinal Stromal Tumors 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Capecitabine 42Oxaliplatin 39Fluorouracil 29Leucovorin 23Radiotherapy 22Cetuximab 15Bevacizumab 15Irinotecan 13Nivolumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 9Drug Therapy 9Surgical Procedures, Operative 8Folfox protocol 8pembrolizumab 7Radiotherapy, Intensity-Modulated 7Chemoradiotherapy 7Biopsy 7trifluridine tipiracil drug combination 6Radiation 6tislelizumab 5sintilimab 5regorafenib 5dehydroftorafur 5X-Rays 5Surveys and Questionnaires 5Sigmoidoscopy 5Endoscopy 5Consolidation Chemotherapy 5spartalizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Clobetasol × 1 year × Clear all
NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Completed
123 enrolled 21 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡